The trajectory of companies tied to Viagra's history presents a complex investment picture . While the initial surge generated substantial profits , generic competition have significantly eroded sales . Investing in connected pharmaceutical companies now requires a careful assessment of proprietary rights , evolving medical shifts , and the prospec